

# 1 **Detection of airborne respiratory viruses in pediatric patient rooms in**

## 2 **Guangzhou, China**

3 Yanmin Xie<sup>1\*</sup>, Eunice Yuen Chi Shiu<sup>1\*</sup>, Dan Ye<sup>2\*</sup>, Wenjie Zhang<sup>3</sup>, Wenbo Huang<sup>3</sup>, Zifeng

4 Yang<sup>3†</sup>, Benjamin John Cowling<sup>1,4†</sup>, Nancy Hiu Lan Leung<sup>1,4</sup>

5 \*These authors contributed equally to this work.

6 †ZY and BJC should be considered joint corresponding authors.

7

### 8 **Affiliations:**

9 1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of  
10 Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam,  
11 Hong Kong SAR, China

12 2. Department of Infection Control, The First Affiliated Hospital of Guangzhou Medical  
13 University, Guangzhou, China

14 3. State Key Laboratory of Respiratory Diseases, National Clinical Research Center for  
15 Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital  
16 of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China

17 4. Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong  
18 Kong Special Administrative Region, China

19

### 20 **Corresponding author:**

21 Zifeng Yang, State Key Laboratory of Respiratory Disease, National Clinical Research Center  
22 for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, 151  
23 Yanjiangxi Road, Yuexiu District, Guangzhou, Guangdong 510120, China.

24 Tel: +86 136 2227 3918; email: [jeffyah@163.com](mailto:jeffyah@163.com).

25 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

26 **Alternate corresponding author:**

27 Benjamin J. Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The

28 University of Hong Kong, 7 Sassoon Road, Pokfulam, Hong Kong.

29 Tel: +852 3917 6711; email: [bcowling@hku.hk](mailto:bcowling@hku.hk).

30

31 Word count (abstract): 248

32 Word count (main text): 2,949

33

34

35 **ABSTRACT**

36 **Background:** Despite the controversy of aerosol transmission for different respiratory viruses,  
37 there are few direct comparisons. Respiratory virus detection in the air can inform transmission  
38 risk assessment in healthcare settings. We aimed to identify five common respiratory viruses in  
39 the air in pediatric patient rooms.

40 **Methods:** We sampled air with two-stage cyclone samplers continuously for 4 hours in 5-bed  
41 pediatric patient rooms in a tertiary hospital in China. Respiratory virus RNA/DNA recovered  
42 in the air were quantified by PCR.

43 **Results:** We conducted air sampling on 44 occasions from December 2017 through January  
44 2020, and identified 24, 18, 16, 4 and 8 occasions which had  $\geq 1$  patient in the room tested  
45 positive for respiratory syncytial virus (RSV), adenovirus (AdV), parainfluenza virus (PIV),  
46 influenza B or A virus, respectively. Detection of influenza A viral gene copies was most  
47 frequent even when there were no known infected patients in the room (72%). Influenza B,  
48 AdV and RSV were detected in low to moderate frequencies, whether there were infected  
49 patients in close proximity (13-50%) or not (12-25%). PIV was rarely detected even when air  
50 samplers were placed in close proximity to infected patients (8%). About  $10^3$ – $10^5$  copies/m<sup>3</sup>  
51 were detected for all detected respiratory viruses.

52 **Conclusions:** Healthcare workers and visitors likely have substantial exposure to various  
53 respiratory viruses including influenza A/B viruses, RSV and AdV in pediatric patient rooms,  
54 even in the absence of infected individuals in close proximity, suggesting the potential value of  
55 improving indoor ventilation or air disinfection in hospitals.

56

57

58

## 59 INTRODUCTION

60 Acute respiratory infections are a leading cause of morbidity and mortality in children globally,  
61 with the burden disproportionately falling in lower-income locations [1]. Common respiratory  
62 virus infections in children include respiratory syncytial virus (RSV), adenovirus (AdV),  
63 parainfluenza virus (PIV), influenza A virus and influenza B virus [2,3]. Respiratory virus  
64 infections have been thought to transmit via respiratory droplets of various sizes including fine  
65 particle aerosols. Contact and droplet precautions are currently recommended for most common  
66 respiratory viruses in healthcare settings [4]. The potential need for aerosol precautions,  
67 however, remains controversial for influenza virus [5,6] and has lacked attention for other  
68 respiratory viruses [7,8]. Epidemiologic studies have reported the molecular detection of RSV  
69 in the air both in droplets [9,10] and fine particles [11,12]. Few studies have investigated the  
70 possibility of airborne AdV [13-16] and PIV [17,18] transmission in healthcare settings.  
71 Furthermore, similar studies were usually conducted in single-bed or two-bed wards in higher  
72 income locations [12,13,19], and few were conducted in hospitals [20]. Given heightened  
73 awareness of the potential of other respiratory viruses transmitting through the airborne route  
74 [4,21], here we report an extension of our previous study on influenza [22] to other respiratory  
75 viruses, to quantify the detection and concentration of virus-laden particles and factors of  
76 contribution in the air. This study was conducted prior to the COVID-19 pandemic.

77

## 78 METHODS

### 79 *Study design*

80 The study was conducted in a tertiary hospital in Guangzhou, China from December 2017  
81 through January 2020, using different inclusion criteria but similar air sampling and sample  
82 processing procedures as described in our previous study [22]. All pediatric patients ( $\leq 14$  years  
83 old) were screened routinely by reverse transcription polymerase chain reaction (PCR) for

84 respiratory virus infection using throat swabs at admission. An air sampling occasion was  
85 triggered when a patient room had at least one patient (“target” patient) who was admitted for  
86 acute respiratory symptoms and was PCR-positive for influenza B virus, RSV, AdV or PIV  
87 infection. Influenza A virus was not considered when triggering air sampling to increase the  
88 chance of identifying other respiratory virus infections, although the samples we collected were  
89 still tested for influenza A virus. If more than one patient was identified on the same day,  
90 patients with a higher body temperature measured at admission or with a more recent symptom  
91 onset was selected.

92  
93 We then conducted continuous air sampling for 4 hours, by setting two two-stage cyclone air  
94 samples developed by the US National Institute of Occupational Safety and Health (NIOSH)  
95 in the room [23]. One sampler was placed as close to the bed of the target patient as possible  
96 near the patients’ head (‘closer’ NIOSH sampler), and the other was placed close to the patient  
97 next to the target patient further away from the bed (‘further’ NIOSH sampler). The NIOSH  
98 samplers were fixed 1.3m from the floor so that they were the same height as the children's  
99 head when sitting on the bed. The NIOSH samplers collected air particles in 3 different size-  
100 fractions of 1 $\mu$ m, 1-4 $\mu$ m and >4 $\mu$ m at a flow rate of 3.5 L/min. Other information including  
101 basic environmental parameters (temperature, relative humidity and CO<sub>2</sub>), the number of  
102 visitors and health care workers visiting the room, door/windows opening situation, and  
103 nebulizer therapy conducted while sampling was collected at the start and again after 2 hours  
104 and 4 hours.

105

### 106 ***Ethical approval***

107 The Institutional Review Board of the University of Hong Kong, and the First Affiliated  
108 Hospital of Guangzhou Medical University approved this study. All patients and parents or

109 legal guardians provided verbal informed consent. Written consent was deemed unnecessary,  
110 given that the study involved environmental air sampling and information on patients' diagnoses  
111 was collected anonymously with no personal identifying information.

112

### 113 *Laboratory methods*

114 RNA or DNA from the respiratory virus in air samplers was extracted by QIAamp RNA Mini  
115 Kit or QIAamp Viral RNA Mini kit (Qiagen Co. Ltd., Shanghai, China) using the  
116 manufacturer's protocols [24]. Five respiratory viruses, including influenza A virus, influenza  
117 B virus, RSV, AdV and PIV, were tested by real-time PCR using Taqman designed primers and  
118 probes, TaKaRa reagent and protocol as previously described [25]. We considered samples with  
119 a clear reaction signal growth curve and Ct value  $\leq 40$  as positive, corresponding to lower limits  
120 of detection from 143 to 875 copies/m<sup>3</sup> in our air samples.

121

### 122 *Statistical methods*

123 For each virus, we divided all the air sampling occasions into either of the two categories,  
124 whether (Scenario 1) there was at least one patient in the room who was tested positive for the  
125 infection, or (Scenario 2) none of the patients in the room was tested positive for the infection.  
126 We further divided the first category into two sub-categories, (Scenario 1a) the air sampler was  
127 placed where at least one of the patients in the two adjacent beds ("neighboring" patients) tested  
128 positive for the infection, regardless of whether any of the other patients in the room also tested  
129 positive or not, or (Scenario 1b) the air sampler was placed where both neighboring patients in  
130 the adjacent beds tested negative for the virus, but in the same room there were other patient(s)  
131 who tested positive. To identify any difference between the virus for each scenarios (1a, 1b, 2),  
132 we compared the frequency of occasions with virus RNA/DNA recovery in the air for each air  
133 size fractions ( $<1\mu\text{m}$ ,  $1-4\mu\text{m}$  and  $>4\mu\text{m}$ ) by Chi-square test or Fisher's exact test. We also

134 translated Ct values in the original samples to copies/m<sup>3</sup> air based on flow rates. All analyses  
135 were conducted with R version 4.0.5 (R Foundation for Statistical Computing, Vienna, Austria).

136

## 137 **RESULTS**

138 We collected air samples on 44 occasions from December 2017 to January 2020. Since we used  
139 two samplers on each occasion, and there were three size fractions in each sampler, we obtained  
140 in total 264 air samples for laboratory analysis. Patients triggering the air sampling included 15  
141 (34%) patients with RSV, 14 (32%) with AdV, 12 (27%) with PIV and 3 (7%) with influenza  
142 B virus. These target patients had been admitted for a mean of 3.5 days (interquartile range,  
143 IQR 2.0-4.0) prior to sampling, and this was similar across viruses: 2.9 days (IQR 2.0-3.3) for  
144 RSV, 3.2 (IQR 2.3-3.0) for AdV, 4.4 days (IQR 1.3-4.8) for PIV and 3.1 days (IQR 2.4-3.9) for  
145 influenza B. For the 44 air sampling occasions, the average measured room temperature,  
146 relative humidity, and CO<sub>2</sub> (ppm) were 25°C (IQR 23-26), 63% (IQR 49-78) and 1003 ppm  
147 (IQR 786-1224), respectively (Table 1). On average, at least 3 visitors and a maximum of 9  
148 healthcare workers were present in the room.

149

150 In total, there were 239 pediatric patients present in the rooms during the 44 sampling occasions.  
151 These 239 patients had an average age of 3.3 years old (IQR 0.9-4.5), with a mean hospital stay  
152 of 8 days (IQR 4-10) between admission and discharge. Nebulization therapy was frequently  
153 conducted, with 80% of our sampling occasions having at least 3 patients conducting  
154 nebulization therapy before or during the air sampling on the same day. Information on  
155 laboratory testing results was available for 222/239 (93%), including 110/239 (46%) who were  
156 positive for RSV, AdV, PIV, influenza B or influenza A (Table 1). From the 44 air sampling  
157 occasions we identified occasions which had at least one patient in the room who tested positive

158 for a particular respiratory virus, including 24 (55%) for RSV, 18 (41%) for AdV, 16 (36%) for  
159 PIV, 4 (9%) for influenza B and 8 (20%) occasions for influenza A (Table 1).

160

161 We classified the 44 air sampling occasions into one of the three scenarios of whether there  
162 were patients with confirmed infection in the room for each respiratory virus, and present the  
163 frequency of occasions with respiratory virus recovery in the air at any of the three air size  
164 fractions (Table 2), or stratified by the three size fractions (Table 3), and viral load identified  
165 in each of the three air size fractions (Figure 1). The three scenarios were: *Scenario 1a* –  
166 occasions with neighboring patients positive for the corresponding RV infection; *Scenario 1b*  
167 – occasions with neighboring patients negative but other patients in the room positive for the  
168 corresponding RV infection; and *Scenario 2* – occasions where no patients in the room was  
169 positive for the corresponding respiratory virus infection. We also present the data in a subset  
170 of sampling occasions which the neighboring patients were the only patients in the room  
171 positive for the infection (Table 4). Separately, for Scenarios 1a and 1b, we also compared the  
172 respiratory virus recovery between whether the target patient had undergone nebulization or not  
173 during the air sampling (Table 5).

174

175 Among all 44 air sampling occasions, influenza A gene copies was more frequently detected in  
176 the air (70%), followed by influenza B (27%), RSV (27%) and AdV (23%), and PIV (5%) was  
177 rarely detected (Table 2). However, all respiratory viruses were recovered in the air in patient  
178 rooms even in the absence of known confirmed patients in the rooms, with significant difference  
179 in the detection between respiratory viruses, and observed most frequent recovery for influenza  
180 A (72%), RSV (30%) and influenza B (25%) and less for AdV (12%) and PIV (4%) (Scenario  
181 2). If restricting to air sampling occasions where at least one patient in the room who had  
182 confirmed infection for the corresponding virus, we observed virus recovery in the air for all



183 RVs when there were infected patients in close proximity (Scenario 1a); and even virus  
184 recovery when there were no known infected patients in close proximity for influenza A (4/6  
185 occasions, 67%), RSV (4/8 occasions, 50%) and AdV (1/2 occasion, 50%), while the study was  
186 underpowered for the other two viruses (Scenario 1b).

187

188 Viral gene copies were recovered in all air size fractions for all respiratory viruses except PIV  
189 (Table 3, Figure 1). Despite the presence of confirmed patients in close proximity (Scenario  
190 1a), we observed only small proportions (mostly <20%) of occasions with virus recovery for  
191 RSV, AdV and PIV, and no observed difference between size fractions. Virus recovery in all  
192 size fractions was observed when known infected patients were not present in close proximity  
193 but in the same room for RSV and INFA (Scenario 1b). Even when there were no known  
194 patients with the confirmed infection in the room (Scenario 2), we could recover viral gene  
195 copies in all size fractions for influenza A virus, RSV and INFB, furthermore for influenza A  
196 apparently there were higher proportions of virus recovery in the larger particles (Table 3).  
197 When restricting to air sampling occasions which the neighboring patients were the only  
198 patients in the room positive for the infection, viral gene copies were recovered in less than  
199 15% of all fractions for RSV and AdV, and none of all fractions for PIV (Table 4).

200

201 More than 60% of the 145/239 pediatrics patients conducted nebulizer therapy during the 44  
202 air sampling occasions, and nebulizers were used by at least 3 patients during air sampling for  
203 34/44 (80%) of occasions. We did not find an association between the frequency of nebulizer  
204 use and the detection of respiratory viruses in our air samples (Table 5).

205

## 206 **DISCUSSION**

207 We conducted a 2-year air sampling study in pediatric rooms before the COVID-19 pandemic  
208 and tested for five of the most common respiratory viruses in children. We had expected the  
209 detection of respiratory virus RNA/DNA to occur more frequently when we placed the sampler  
210 next to a patient with that viral infection and less likely on other occasions, but this was not  
211 always the case (Table 4). We frequently detected influenza A virus in our samples even when  
212 there was no patient in the room with confirmed influenza A virus infection, consistent with the  
213 findings in our earlier study in the same setting which focused on influenza [22], which was  
214 expected because influenza A was circulating in the community during the air sampling, and  
215 Xie et al. reported that increased crowdedness was associated with a higher frequency of  
216 detection of virus-laden particles [5]. In the present study, we showed that this also occurred to  
217 a lesser extent with influenza B virus and RSV (Table 2).

218  
219 These findings are compatible with other observations of influenza virus [26,27] or RSV  
220 [11,19,28] detection in the air far from the presumed source in healthcare settings. Aintablian  
221 et al. frequently identified RSV RNA in pediatric patient rooms at distances as far as 7m from  
222 the patient bedside [19]. In our study, 30% of RSV was recovered in the air in patient rooms  
223 even in the absence of known confirmed patients in the rooms, while Grayson et al. reported  
224 detection of RSV in air samples on 4/8 sampling days without RSV confirmed patients in the  
225 pediatric exam rooms and most of the RSV-laden particles were larger than 4 $\mu$ m [10]. The  
226 present study suggests that respiratory viruses recovered from the air in patient rooms may be  
227 from patients in close proximity, from other more distant patients in the same room, or even  
228 perhaps from other sources in the hospital such as patients in other rooms, healthcare workers  
229 or visitors [11].

230

231 The less frequent detection of AdV and especially rarely for PIV in our air samples might  
232 perhaps be indicative of a lower chance of transmission via the aerosol route for these  
233 respiratory viruses. We observed that AdV was more frequently recovered in the air when the  
234 sampler was placed next to an infected patient but less when there were no infected patients in  
235 close proximity (Figure 1). However, AdV was frequently detected in studies in pediatric  
236 emergency rooms in Taiwan [13] and Brazil [16], and general pediatric wards in Singapore  
237 [29]. There were also occasional reports of AdV outbreaks in healthcare settings such as a  
238 children's hospital [30] and a pediatric care facility [31]. We detected AdV in all size fractions,  
239 mostly from patients with confirmed AdV infection at admission, suggesting an opportunity for  
240 infection control through rapid diagnosis at admission if nosocomial AdV outbreaks occur.

241  
242 Rare detection of PIV in the air from the environment was also reported in most of other studies  
243 [17,32,33]. Mclean et al. used Anderson samplers and detected PIV in air samples collected  
244 from 1/30 children sampled [17]. Goyal et al. reported the presence of PIV in 1/64 used  
245 ventilation filters in public buildings [32]. Another study in Korea reported a total detection  
246 rate of 0.5% in air samples collected in a community setting [33]. In contrast to these evidence,  
247 Galton et al. identified PIV RNA in exhaled breath or cough samples collected from 13/53  
248 (26%) infected children and adults [18], and animal studies showed that airborne transmission  
249 of murine PIV (Sendai virus) was 86-100% efficient [34] and short-range airborne transmission  
250 was warranted [35]. More studies, perhaps on the stability of PIV in aerosols, may help to  
251 explain the discrepancy.

252  
253 The potential for aerosol generating procedures to increase the risk of nosocomial transmission  
254 have been suggested [36]. In our study patients were often prescribed nebulizer therapy, but we  
255 did not find an association between nebulizer therapy and the detection rates of virus (Table 5).

256 This may be because coughing of patients in the ward had already generated virus-laden  
257 aerosols which were detected in our samplers [18], whether or not aerosol generating  
258 procedures were also used.

259

260 The high levels of viral gene copies at the scale of  $10^3$ - $10^5$  copies/ $m^3$  air detected in our study  
261 in 5-bed pediatric patient rooms, particularly for influenza A and B viruses and RSV (Figure  
262 1), are similar to another study in pediatric outpatient clinics [13] but contrast to the low levels  
263 reported in the air in other studies in adult patient rooms [37]. Previously we reported a  
264 ventilation rate of 1.5 air changes per hour in a similar but unoccupied patient room in the same  
265 hospital [22], and low ventilation may allow the accumulation of respiratory viruses in the air  
266 to higher concentrations. Alternatively, patients for whom we placed the air samplers nearby  
267 may be earlier in their disease course, so that viral shedding may tend to be higher [38], and  
268 children may shed more virus than adults in general. However, our study did not show higher  
269 virus recovery when there were infected patients in close proximity (Table 4). We also have  
270 limited understanding on the viral shedding kinetics and their relationship with symptom onset  
271 for many respiratory viruses.

272

273 Our study has several limitations. First, we did not culture virus among the recovered air  
274 samples, since we expected low isolation rate based on our previous study on influenza in the  
275 same setting [22]. Second, we were not able to identify the source of generation of virus  
276 detected in the air nor transmission via the aerosol route among children. It is possible that  
277 infected staff or visitors who visited the room during the air sampling were responsible for some  
278 of the virus detected in the air. Virus sequencing could be used in future studies to help identify  
279 the source of virus detections. Third, we did not measure the ventilation rate during the  
280 sampling occasions, but referred to data from our previous study [22], but human and other

281 environmental movement such as opening and closing windows, doors, and drying racks might  
282 affect ventilation rates.

283

284 In conclusion, influenza A/B viruses and RSV were frequently detected in the air in pediatric  
285 rooms, including frequently in rooms where no patients in the room tested positive for the  
286 corresponding virus infection. PIV was rarely detected. We did not find an association of virus  
287 detection with the use of nebulizer therapy. Our results indicate the potential benefits of  
288 improving personal protective equipment for staff and visitors, and/or improving indoor  
289 ventilation, both within patient rooms with known infected patients or in all healthcare settings  
290 in general. The latter may be achieved by increasing air changes through natural or mechanical  
291 ventilation, or perhaps air disinfection with ultraviolet light [4].

292

293

294 **ACKNOWLEDGEMENTS**

295 We wish to acknowledge Weijia Xiong for statistical support, colleagues from the Department  
296 of Infection Control and the State Key Laboratory of Respiratory Diseases at the First Affiliated  
297 Hospital of Guangzhou Medical University for technical support; and Dr William Lindsley  
298 from the US Centers for Disease Control and Prevention for providing the air samplers. This  
299 work was supported in part by the Theme-based Research Scheme from the Research Grants  
300 Council of the Hong Kong Special Administrative Region, China [Project No. T11-712/19-N],  
301 the Guangzhou Medical University High-level University Clinical Research and Cultivation  
302 Program [Guangzhou Medical University released [2017] No. 160]; the Guangzhou Medical  
303 University High- level University Innovation Team Training Program [Guangzhou Medical  
304 University released [2017] No. 159]; and the Science Research Project of the Guangdong  
305 Province, China [Grant No. 2016A050503047].

306

307 **POTENTIAL CONFLICTS OF INTEREST**

308 BJC has received honoraria from AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna,  
309 Pfizer, Roche and Sanofi Pasteur. The authors report no other potential conflicts of interest.

310

311

## 312 **References**

- 313 1. G. B. D. Lower Respiratory Infections Collaborators. Quantifying risks and  
314 interventions that have affected the burden of lower respiratory infections among  
315 children younger than 5 years: an analysis for the Global Burden of Disease Study 2017.  
316 *Lancet Infect Dis* **2020**; 20(1): 60-79.
- 317 2. Li J, Tao Y, Tang M, et al. Rapid detection of respiratory organisms with the FilmArray  
318 respiratory panel in a large children's hospital in China. *BMC Infect Dis* **2018**; 18(1):  
319 510.
- 320 3. Chiu SS, Chan KH, Chen H, et al. Virologically confirmed population-based burden of  
321 hospitalization caused by respiratory syncytial virus, adenovirus, and parainfluenza  
322 viruses in children in Hong Kong. *Pediatr Infect Dis J* **2010**; 29(12): 1088-92.
- 323 4. Leung NHL. Transmissibility and transmission of respiratory viruses. *Nat Rev*  
324 *Microbiol* **2021**; 19(8): 528-45.
- 325 5. Brankston G, Gitterman L, Hirji Z, Lemieux C, Gardam M. Transmission of influenza  
326 A in human beings. *Lancet Infect Dis* **2007**; 7(4): 257-65.
- 327 6. Tellier R. Review of aerosol transmission of influenza A virus. *Emerg Infect Dis* **2006**;  
328 12(11): 1657-62.
- 329 7. Kutter JS, Spronken MI, Fraaij PL, Fouchier RAM, Herfst S. Transmission routes of  
330 respiratory viruses among humans. *Curr Opin Virol* **2018**; 28: 142-51.
- 331 8. Shiu EYC, Leung NHL, Cowling BJ. Controversy around airborne versus droplet  
332 transmission of respiratory viruses: implication for infection prevention. *Curr Opin*  
333 *Infect Dis* **2019**; 32(4): 372-9.
- 334 9. Kutter JS, de Meulder D, Bestebroer TM, et al. Small quantities of respiratory syncytial  
335 virus RNA only in large droplets around infants hospitalized with acute respiratory  
336 infections. *Antimicrob Resist Infect Control* **2021**; 10(1): 100.

- 337 10. Grayson SA, Griffiths PS, Perez MK, Piedimonte G. Detection of airborne respiratory  
338 syncytial virus in a pediatric acute care clinic. *Pediatr Pulmonol* **2017**; 52(5): 684-8.
- 339 11. Lindsley WG, Blachere FM, Davis KA, et al. Distribution of airborne influenza virus  
340 and respiratory syncytial virus in an urgent care medical clinic. *Clin Infect Dis* **2010**;  
341 50(5): 693-8.
- 342 12. Kulkarni H, Smith CM, Lee DDH, Hirst RA, Easton AJ, O’Callaghan C. Evidence of  
343 respiratory syncytial virus spread by aerosol. Time to revisit infection control strategies?  
344 *Am J Respir Crit Care Med* **2016**; 194(3): 308-16.
- 345 13. Tseng CC, Chang LY, Li CS. Detection of airborne viruses in a pediatrics department  
346 measured using real-time qPCR coupled to an air-sampling filter method. *J Environ*  
347 *Health* **2010**; 73(4): 22-8.
- 348 14. Wan GH, Huang CG, Huang YC, et al. Surveillance of airborne adenovirus and  
349 *Mycoplasma pneumoniae* in a hospital pediatric department. *PLoS One* **2012**; 7(3):  
350 e33974.
- 351 15. Nguyen TT, Poh MK, Low J, et al. Bioaerosol sampling in clinical settings: a promising,  
352 noninvasive approach for detecting respiratory viruses. *Open Forum Infect Dis* **2017**;  
353 4(1): ofw259.
- 354 16. Cabral CZ, Guaragna JBA, Amantéa FC, et al. Distribution of airborne respiratory  
355 pathogens in pediatric emergency department waiting room. *Pediatr Pulmonol* **2021**;  
356 56(8): 2724-8.
- 357 17. McLean DM, Bannatyne RM, Givan KF. Myxovirus dissemination by air. *Can Med*  
358 *Assoc J* **1967**; 96(22): 1449-53.
- 359 18. Gralton J, Tovey ER, McLaws ML, Rawlinson WD. Respiratory virus RNA is  
360 detectable in airborne and droplet particles. *J Med Virol* **2013**; 85(12): 2151-9.



- 361 19. Aintablian N, Walpita P, Sawyer MH. Detection of Bordetella pertussis and respiratory  
362 syncytial virus in air samples from hospital rooms. *Infect Control Hosp Epidemiol* **1998**;  
363 19(12): 918-23.
- 364 20. Wan GH, Huang CG, Chung FF, Lin TY, Tsao KC, Huang YC. Detection of common  
365 respiratory viruses and Mycoplasma pneumoniae in patient-occupied rooms in pediatric  
366 wards. *Medicine (Baltimore)* **2016**; 95(14): e3014.
- 367 21. Wang CC, Prather KA, Sznitman J, et al. Airborne transmission of respiratory viruses.  
368 *Science* **2021**; 373(6558): eabd9149.
- 369 22. Shiu EYC, Huang W, Ye D, et al. Frequent recovery of influenza A but not influenza B  
370 virus RNA in aerosols in pediatric patient rooms. *Indoor Air* **2020**; 30(5): 805-15.
- 371 23. Lindsley WG, Schmechel D, Chen BT. A two-stage cyclone using microcentrifuge  
372 tubes for personal bioaerosol sampling. *J Environ Monit* **2006**; 8(11): 1136-42.
- 373 24. Liu WK, Liu Q, Chen DH, et al. Epidemiology and clinical presentation of the four  
374 human parainfluenza virus types. *BMC Infect Dis* **2013**; 13: 28.
- 375 25. Liu WK, Chen DH, Liu Q, et al. Detection of human bocavirus from children and adults  
376 with acute respiratory tract illness in Guangzhou, southern China. *BMC Infect Dis* **2011**;  
377 11: 345.
- 378 26. Blachere FM, Lindsley WG, Pearce TA, et al. Measurement of airborne influenza virus  
379 in a hospital emergency department. *Clin Infect Dis* **2009**; 48(4): 438-40.
- 380 27. Bischoff WE, Swett K, Leng I, Peters TR. Exposure to influenza virus aerosols during  
381 routine patient care. *J Infect Dis* **2013**; 207(7): 1037-46.
- 382 28. Habibi N, Uddin S, Al-Salameen F, et al. SARS-CoV-2, other respiratory viruses and  
383 bacteria in aerosols: Report from Kuwait's hospitals. *Indoor Air* **2021**; 31(6): 1815-25.
- 384 29. Yadana S, Coleman KK, Nguyen TT, et al. Monitoring for airborne respiratory viruses  
385 in a general pediatric ward in Singapore. *J Public Health Res* **2019**; 8(3): 1407.

- 386 30. Hatherill M, Levin M, Lawrenson J, Hsiao NY, Reynolds L, Argent A. Evolution of an  
387 adenovirus outbreak in a multidisciplinary children's hospital. *J Paediatr Child Health*  
388 **2004**; 40(8): 449-54.
- 389 31. James L, Vernon MO, Jones RC, et al. Outbreak of human adenovirus type 3 infection  
390 in a pediatric long-term care facility—Illinois, 2005. *Clin Infect Dis* **2007**; 45(4): 416-  
391 20.
- 392 32. Hwang SJ YH, Ku PT, Sim JH, Cha YW, Lee MO. Distribution and Characterization  
393 of Airborne Respiratory Pathogens in Public Facilities. *J Bacteriol Virol* **2018**; 48(4):  
394 121-9.
- 395 33. Park KT MK, Kim HT, Park CJ, Jeong HC, Lim YH. Detection of Airborne Respiratory  
396 Viruses in Residential Environments. *J Environ Health Sci* **2011**; 37(4): 306-14.
- 397 34. Burke GR, Thomas SA, Eum JH, Strand MR. Mutualistic polydnviruses share essential  
398 replication gene functions with pathogenic ancestors. *PLoS Pathog* **2013**; 9(5):  
399 e1003348.
- 400 35. Burke CW, Bridges O, Brown S, Rahija R, Russell CJ. Mode of parainfluenza virus  
401 transmission determines the dynamics of primary infection and protection from  
402 reinfection. *PLoS Pathog* **2013**; 9(11): e1003786.
- 403 36. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures  
404 and risk of transmission of acute respiratory infections to healthcare workers: a  
405 systematic review. *PLoS One* **2012**; 7(4): e35797.
- 406 37. Leung NHL, Zhou J, Chu DK, et al. Quantification of Influenza Virus RNA in Aerosols  
407 in Patient Rooms. *PLoS One* **2016**; 11(2): e0148669.
- 408 38. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation  
409 periods of acute respiratory viral infections: a systematic review. *Lancet Infect Dis*  
410 **2009**; 9(5): 291-300.

411

**Table 1. Characteristic of sampling occasions with at least one patient positive for the corresponding respiratory virus infection (Scenario 1).**

Occasions which at least one patient in the room positive for the corresponding respiratory virus infection	<b>RSV (n=24)</b>	<b>AdV (n=18)</b>	<b>PIV (n=16)</b>	<b>Influenza B (n=4)</b>	<b>Influenza A (n=8)</b>	<b>All occasions (n=44)</b>
Patients No.	133	95	84	23	42	239
CO <sub>2</sub> (ppm) (IQR)	959 (772 - 1132)	1048 (817 - 1242)	1059 (883 - 1222)	754 (668 - 840)	922 (716 - 1084)	1003 (786 - 1224)
Room temperature (°C) (IQR)	24 (23 - 25)	25 (23 - 26)	25 (24 - 26)	23 (23 - 23)	25 (24 - 26)	25 (23 - 26)
Relative humidity (%) (IQR)	68 (50 - 86)	63 (51 - 68)	66 (55 - 71)	42 (33 - 47)	57 (47 - 59)	63 (49 - 78)
Healthcare workers (HCWs) No. (range)	≤9 (0 - 9)	≤9 (0 - 9)	≤3 (0 - 3)	≤7 (0 - 4)	≤9 (0 - 9)	≤9
Visitors No. (range)	≥3 (3 - 10)	≥3 (3 - 10)	≥4 (4 - 10)	≥4 (4 - 8)	≥4 (4 - 10)	≥3
Patients conducted nebulizer therapy in the room No. (%)	82/113 (73)	66/95 (69)	55/84 (65)	10/23 (43)	26/42 (62)	145/239 (61)
<b><i>Patients in the room who were tested positive for a particular respiratory virus No. (%)</i></b>						
RSV	34	9	13	0	2	34
AdV	8	18	3	1	5	18
PIV	8	3	19	0	3	19
Influenza B	0	1	0	5	1	5
Influenza A	2	5	3	1	8	8

**Table 2. Frequency of occasions with respiratory virus RNA/DNA detection in the air in any air size fractions for five respiratory viruses.**

	RSV	AdV	PIV	Flu B	Flu A	p value
	No. of occasions positive / Total no. of occasions (%)					
<i>Air sampling occasions</i>						
Occasions which at least one patient in the room positive for the corresponding respiratory virus infection (Scenario 1a + 1b)	24/44 (55)	18/44 (41)	16/44 (36)	4/44 (9)	8/44 (20)	-
<i>Respiratory virus RNA/DNA recovery in the air</i>						
Occasions with the corresponding respiratory virus RNA/DNA recovered in the air	12/44 (27)	10/44 (23)	2/44 (5)	12/44 (27)	31/44 (70)	-
Respiratory virus recovery rate in occasions with neighboring patients positive for the corresponding virus infection (Scenario 1a)	2/16 (13)	6/16 (38)	1/13 (8)	2/4 (50)	1/2 (50)	0.1
Respiratory virus recovery rate in occasions with neighboring patients negative but other patients in the room positive for the corresponding virus infection (Scenario 1b)	4/8 (50)	1/2 (50)	0/3 (0)	0/0 (0)	4/6 (67)	0.3
Respiratory virus recovery rate in occasions where no patients in the room were positive for the corresponding virus infection (Scenario 2)	6/20 (30)	3/26 (12)	1/28 (4)	10/40 (25)	26/36 (72)	<0.001

RSV: respiratory syncytial virus; AdV: adenovirus; PIV: parainfluenza virus.

**Table 3. Frequency of occasions with respiratory virus RNA/DNA detection in the air in three air size fractions (<1µm, 1-4µm and >4µm) for five respiratory viruses.**

	Neighboring patients positive for the corresponding respiratory virus infection (Scenario 1a)					Neighboring patients negative but other patients in the room positive for the corresponding respiratory virus infection (Scenario 1b)					No patients in the room were positive for the corresponding respiratory virus infection (Scenario 2)				
	N	<1µm n (%)	1-4µm n (%)	>4µm n (%)	p value	N	<1µm n (%)	1-4µm n (%)	>4µm n (%)	p value	N	<1µm n (%)	1-4µm n (%)	>4µm n (%)	p value
RSV	<b>16</b>	1 (6.3)	0 (0)	1 (6.3)	>0.99	<b>8</b>	2 (25)	1 (13)	2 (25)	>0.99	<b>20</b>	3 (15)	5 (25)	5 (25)	0.79
AdV	<b>16</b>	3 (19)	2 (13)	2 (13)	>0.99	<b>2</b>	1 (50)	0 (0)	0 (0)	>0.99	<b>26</b>	0 (0)	1 (3.8)	2 (7.7)	0.77
PIV	<b>13</b>	0 (0)	0 (0)	1 (8.7)	>0.99	<b>3</b>	0 (0)	0 (0)	0 (0)	>0.99	<b>28</b>	0 (0)	1 (3.6)	0 (0)	>0.99
Flu B	<b>4</b>	1 (25)	2 (50)	0 (0)	0.71	<b>0</b>	-	-	-	>0.99	<b>40</b>	3 (7.5)	4 (10)	7 (18)	0.46
Flu A	<b>2</b>	1 (50)	1 (50)	0 (0)	>0.99	<b>6</b>	3 (50)	2 (38)	3 (38)	>0.99	<b>36</b>	10 (28)	17 (47)	19 (53)	0.09

RSV: respiratory syncytial virus; AdV: adenovirus; PIV: parainfluenza virus; N: number of occasions

**Table 4. Frequency of occasions with respiratory virus RNA/ DNA detection in the air in three air size fractions (<1µm, 1-4µm and >4µm) for five respiratory viruses, restricted to occasions which the neighboring patients were the only patients in the room positive for the infection.**


	N	Closer NIOSH sampler				Further NIOSH sampler			
		Any fraction	<1µm	1-4µm	>4µm	Any fraction	<1µm	1-4µm	>4µm
		n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
RSV	<b>12</b>	1 (8)	1 (8)	0 (0)	0 (0)	1 (8)	1 (8)	0 (0)	0 (0)
AdV	<b>16</b>	4 (25)	1 (6)	1 (6)	2 (13)	5 (31)	2 (13)	1 (6)	2 (13)
PIV	<b>12</b>	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Influenza B	<b>3</b>	1 (33)	1 (33)	1 (33)	0 (0)	1 (33)	1 (33)	0 (0)	0 (0)
Influenza A	<b>2</b>	1 (50)	1 (50)	1 (50)	0 (0)	1 (50)	0 (0)	1 (50)	0 (0)

RSV: respiratory syncytial virus; AdV: adenovirus; PIV: parainfluenza virus; N: number of occasions

**Table 5. Frequency of respiratory virus detections in the subset of sample collections when nebulizer therapy was being performed for patients with confirmed respiratory virus infection of the corresponding type.**

Respiratory viruses	Respiratory virus recovery rate in occasions with neighboring patients positive for the corresponding virus infection (Scenario 1a)			Respiratory virus recovery rate in occasions with neighboring patients negative but other patients in the room positive for the corresponding virus infection (Scenario 1b)		
	Nebulizer+ve/Virus detected n (%)	Nebulizer+ve /Virus not detected n (%)	p value	Nebulizer+ve/Virus detected n (%)	Nebulizer+ve/Virus not detected n (%)	p value
RSV	1/2 (50)	11/13 (85)	0.37	3/4 (75)	2/4 (50)	>0.99
AdV	5/6 (83)	7/10 (70)	>0.99	1/1 (100)	1/1 (100)	>0.99
PIV	0/1 (0)	11/12 (92)	0.15	0 (0)	3/3 (100)	>0.99
Influenza B	1/2 (50)	1/2 (50)	>0.99	0 (0)	0/0 (0)	>0.99
Influenza A	0/1 (50)	1/1 (100)	>0.99	3/4 (75)	1/2 (50)	>0.99

## FIGURE LEGEND



**Figure 1. Viral load of respiratory virus RNA/ DNA recovered in the air in pediatric patient rooms in three air size fractions (<1μm, 1-4μm and >4μm) for five respiratory viruses.** Respiratory viruses tested including respiratory syncytial virus (RSV), adenovirus (AdV), parainfluenza virus (PIV), influenza B virus and influenza A virus. For each respiratory virus (rows), the air sampling occasions are categorized into three scenarios (columns): *Scenario 1a* – occasions with neighboring patients positive for the corresponding virus infection; *Scenario 1b* – occasions with neighboring patients negative but other patients in the room positive for the corresponding virus infection; and *Scenario 2* – occasions where no patients in the room was positive



for the corresponding virus infection. In each occasion we placed two air samplers in the room, including one sampler placed next to (red) and another sampler (blue) placed further away from the target patient. Viral load is expressed as viral copies per m<sup>3</sup> air sampled, and the limit of detection (LOD) are 143 copies/m<sup>3</sup> for RSV and PIV, 714 copies/m<sup>3</sup> for influenza and 875 copies/m<sup>3</sup> for AdV, respectively.